Are there genetic tests to determine cannabis and pharmacogenetics for PMR treatment?

Posted February 23, 2026 Updated February 23, 2026 Author: Julia Sutton, MSc Reviewed by: Dr. Clarissa Morton, PharmD

Polymyalgia rheumatica (PMR) can bring stiffness, pain, and fatigue that disrupt daily life. As medical cannabis gains attention for symptom control, interest is growing in whether genetic testing can guide safe and effective use. Research into cannabis and pharmacogenetics for PMR looks at how a person’s unique DNA profile may influence their response to cannabis-based therapies.

The idea behind cannabis and pharmacogenetics for PMR is to move beyond general recommendations and instead focus on the individual. By examining specific genes that affect metabolism, tolerance, and sensitivity, doctors may eventually be able to predict which patients benefit most from cannabis and how much they should take.

Potential Benefits of Genetic Insights

Exploring genetic approaches opens up several opportunities for patients. Below are areas where this type of testing could play a role.

Personalised therapy

Genetic results could guide personalised therapy, helping determine which cannabinoids, like CBD or THC, may work best for each patient’s needs.

Genetic testing

Access to genetic testing offers more data for both patients and clinicians. This can reduce trial-and-error approaches, making treatment choices more precise.

Tailored treatment

Combining test results with medical advice could lead to tailored treatment, where dosages and product types align with each individual’s genetic profile.

While still an emerging field, the study of cannabis and pharmacogenetics for PMR highlights how medicine is moving toward greater personalisation. By focusing on personalised therapy, using insights from genetic testing, and applying tailored treatment, patients with PMR may one day benefit from cannabis strategies designed uniquely for them.

If you’re exploring cannabis treatment options for polymyalgia rheumatica, visit providers like LeafEase for personalised consultations and guidance tailored to your needs.

For a deeper dive into the science, diagnosis, and full treatment landscape, read our complete guide to Medical Cannabis and polymyalgia rheumatica.

Written by

Julia Sutton, MSc

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Reviewed by

Dr. Clarissa Morton, PharmD

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.